Tags

Type your tag names separated by a space and hit enter

Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children.
Pediatr Pulmonol. 2006 Mar; 41(3):222-7.PP

Abstract

Montelukast is recommended to be taken in the evening. The effectiveness of this drug to prevent exercise-induced bronchoconstriction (EIB) in children was already evaluated. However, there is no information to determine if this effectiveness could vary depending on dosage time. Children (n = 24) with a documented history of EIB performed an exercise challenge test before starting montelukast treatment. Twelve children were randomly allocated to receive the drug in the morning for 2 weeks, and another 12 to receive it in the evening. After this treatment period and after a week of washout, the children were crossed over. An exercise test was repeated after the first and second periods of treatment. Values obtained after morning or evening dosage were compared with pretreatment values for the whole group of children. There was a significant effect of montelukast for protecting against EIB, measured both as percent of maximum fall in forced expired volume in 1 sec (FEV1) (18.9 +/- 9.7, morning, 18.7 +/- 11.3, evening, vs. 27.5 +/- 9.8, pretreatment; P < 0.05) or as area under the curve (156.4 +/- 102.0, morning, 145.4 +/- 130.6, evening, vs. 294.3 +/- 156.5, pretreatment; P < 0.005). There were no statistical differences between taking the drug in the morning or evening. In conclusion, montelukast, taken for 2 weeks, is equally effective in exercise-induced bronchoconstriction when dosing either in the morning or in the evening.

Authors+Show Affiliations

Allergy Section, Elda General Hospital, Alicante, Spain.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16429427

Citation

Pajaron-Fernandez, Manuel, et al. "Montelukast Administered in the Morning or Evening to Prevent Exercise-induced Bronchoconstriction in Children." Pediatric Pulmonology, vol. 41, no. 3, 2006, pp. 222-7.
Pajaron-Fernandez M, Garcia-Rubia S, Sanchez-Solis M, et al. Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. Pediatr Pulmonol. 2006;41(3):222-7.
Pajaron-Fernandez, M., Garcia-Rubia, S., Sanchez-Solis, M., & Garcia-Marcos, L. (2006). Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. Pediatric Pulmonology, 41(3), 222-7.
Pajaron-Fernandez M, et al. Montelukast Administered in the Morning or Evening to Prevent Exercise-induced Bronchoconstriction in Children. Pediatr Pulmonol. 2006;41(3):222-7. PubMed PMID: 16429427.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. AU - Pajaron-Fernandez,Manuel, AU - Garcia-Rubia,Servando, AU - Sanchez-Solis,Manuel, AU - Garcia-Marcos,Luis, PY - 2006/1/24/pubmed PY - 2006/7/28/medline PY - 2006/1/24/entrez SP - 222 EP - 7 JF - Pediatric pulmonology JO - Pediatr Pulmonol VL - 41 IS - 3 N2 - Montelukast is recommended to be taken in the evening. The effectiveness of this drug to prevent exercise-induced bronchoconstriction (EIB) in children was already evaluated. However, there is no information to determine if this effectiveness could vary depending on dosage time. Children (n = 24) with a documented history of EIB performed an exercise challenge test before starting montelukast treatment. Twelve children were randomly allocated to receive the drug in the morning for 2 weeks, and another 12 to receive it in the evening. After this treatment period and after a week of washout, the children were crossed over. An exercise test was repeated after the first and second periods of treatment. Values obtained after morning or evening dosage were compared with pretreatment values for the whole group of children. There was a significant effect of montelukast for protecting against EIB, measured both as percent of maximum fall in forced expired volume in 1 sec (FEV1) (18.9 +/- 9.7, morning, 18.7 +/- 11.3, evening, vs. 27.5 +/- 9.8, pretreatment; P < 0.05) or as area under the curve (156.4 +/- 102.0, morning, 145.4 +/- 130.6, evening, vs. 294.3 +/- 156.5, pretreatment; P < 0.005). There were no statistical differences between taking the drug in the morning or evening. In conclusion, montelukast, taken for 2 weeks, is equally effective in exercise-induced bronchoconstriction when dosing either in the morning or in the evening. SN - 8755-6863 UR - https://www.unboundmedicine.com/medline/citation/16429427/Montelukast_administered_in_the_morning_or_evening_to_prevent_exercise_induced_bronchoconstriction_in_children_ L2 - https://doi.org/10.1002/ppul.20377 DB - PRIME DP - Unbound Medicine ER -